|View printer-friendly version|
|April 20, 2006 1:37 p.m.|
|Teva Announces Stay of Approval for Generic Pravachol Lifted|
Jerusalem, Israel, April 20, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that further to its press release dated April 19, 2006, Teva filed a motion to reconsider the stay of approval of its Abbreviated New Drug Application (ANDA) to market its generic version of Bristol-Myers Squibb's Pravachol®(Pravastatin Sodium) Tablets, 10 mg, 20 mg and 40 mg, and the Court has granted that motion and vacated the stay of approval. The Court's denial of Apotex's motion for a temporary restraining order and preliminary injunction remains in place. Apotex has appealed those denials to the Court of Appeals for the District of Columbia and has asked that the Appellate Court enter a stay of approval of Teva's ANDA pending a decision on the appeal.